Croda International Plc and The Access to Advanced Health Institute (AAHI) today announced a partnership agreement around innovation and development of adjuvant formulations, under which Croda and AAHI will leverage their combined expertise to make novel vaccine adjuvant formulations globally accessible, thereby advancing next generation, robust and durable vaccines.
AAHI, a leading nonprofit biotech research institute that has developed platform technologies for harnessing the immune system to combat disease, boasts a diverse portfolio of adjuvant formulations used in numerous vaccine candidates targeting major infectious diseases and neglected diseases listed by the World Health Organisation as significant global threats. With deep adjuvant and vaccine formulation expertise and years of experience developing cost-effective, sustainable products and processes for making them, AAHI stands at the forefront of vaccine innovation.
Croda will serve as AAHI’s exclusive authorized manufacturer in major countries, to scale up manufacturing and support for phase 3 clinical trials and commercial use.
About AAHI
AAHI is a nonprofit biotech research institute located in Seattle, Washington, that combines the high-quality science of an academic research organisation with the product development capabilities of a biotech company to help combat some of the world’s deadliest diseases, including infectious diseases such as Covid-19, mosquito- and tick-borne diseases, cancer, fungal and parasitic infections, and other non-communicable diseases. For nearly three decades, AAHI, previously known as the Infectious Disease Research Institute, has focused on creating immune-enhancing technologies that improve the body’s natural response to disease.
Croda Pharma
Croda’s Pharma business is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations, committed to enabling the next generation of drug delivery systems. The business is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms.